Vitiligo after diphencyprone for alopecia areata

Area of Science:

• Dermatology
• Immunotherapy
• Dermatological conditions

Background:

• Topical immunotherapy, including diphencyprone (DPCP), has been a treatment for alopecia areata and warts since the 1970s.
• DPCP is a contact sensitizer used for dermatological conditions stemming from altered immunological states.
• While effective and safe for extensive alopecia areata, DPCP can cause side effects.

Observation:

• Common side effects of DPCP include localized eczema, blistering, lymphadenopathy, and contact urticaria.
• Rare adverse effects encompass erythema multiforme-like reactions, hyperpigmentation, hypopigmentation, and vitiligo.
• This report details a case of vitiligo developing after DPCP therapy for alopecia areata.

Findings:

• A 30-year-old Brazilian male patient developed vitiligo lesions post-DPCP treatment for alopecia areata.
• This case highlights vitiligo as a potential, albeit rare, adverse effect of topical DPCP immunotherapy.
• The development of vitiligo suggests a possible immunological link or reaction to DPCP.

Implications:

• Understanding rare side effects like vitiligo is crucial for managing patients undergoing DPCP therapy.
• Further research may elucidate the specific mechanisms behind DPCP-induced vitiligo.
• This finding contributes to the safety profile documentation of topical immunotherapy for alopecia areata.